Cullinan Oncology Inc. (CGEM): Price and Financial Metrics
CGEM Price/Volume Stats
| Current price | $18.87 | 52-week high | $20.62 |
| Prev. close | $18.89 | 52-week low | $7.64 |
| Day low | $18.23 | Volume | 338,592 |
| Day high | $19.21 | Avg. volume | 488,612 |
| 50-day MA | $17.19 | Dividend yield | N/A |
| 200-day MA | $12.10 | Market Cap | 812.66M |
CGEM Stock Price Chart Interactive Chart >
Cullinan Oncology Inc. (CGEM) Company Bio
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest CGEM News From Around the Web
Below are the latest news stories about CULLINAN ONCOLOGY INC that investors may wish to consider to help them evaluate CGEM as an investment opportunity.
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed’s presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST). A live webcast of the presen |
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesCAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a progra |
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsCullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial CLN-619 clinical biomarker data support mechanism of action and demonstrate monotherapy clinical activity in patients with tumors not typically responsive to checkpoint inhibitor therapy Cash and investment position of $482 million as of September 30, 2023 expected to provide runway into the second half of |
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy Data highlight progress of Cullinan’s diverse pipeline including CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bisp |
Cullinan Oncology to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences: Jeffrey Jones, M.D., M.P.H., M.B.A., Chief Medical Officer, and Jeff Trigilio, Chief Financial Officer will participate in a virtual fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, No |
CGEM Price Returns
| 1-mo | 12.46% |
| 3-mo | 44.38% |
| 6-mo | 123.84% |
| 1-year | 88.32% |
| 3-year | -40.44% |
| 5-year | N/A |
| YTD | 85.18% |
| 2023 | -3.41% |
| 2022 | -31.63% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...